Novavax, Inc. (NVAX)
Largest Insider Buys in Sector
NVAX Stock Price History Chart
NVAX Stock Performance
About Novavax, Inc.
Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial; NanoFlu, a nanoparticle seasonal quadrivalent influenza vaccine candidate that is in Phase 3 clinical trial; and ResVax, a respiratory syncytial virus (RSV) fusion (F) protein nanoparticle vaccine …
Insider Activity of Novavax, Inc.
Over the last 12 months, insiders at Novavax, Inc. have bought $0 and sold $1.07M worth of Novavax, Inc. stock.
On average, over the past 5 years, insiders at Novavax, Inc. have bought $98,977 and sold $55.62M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 1,000 shares for transaction amount of $6,500 was made by Glenn Gregory M (President, R&D) on 2023‑03‑10.
List of Insider Buy and Sell Transactions, Novavax, Inc.
| 2024-06-21 | Sale | director | 7,500 0.0045% | $14.09 | $105,675 | -10.57% | ||
| 2024-06-18 | Sale | director | 7,500 0.0044% | $13.72 | $102,881 | -9.14% | ||
| 2024-06-17 | Sale | President, R&D | 13,904 0.0086% | $14.47 | $201,164 | -10.71% | ||
| 2024-05-14 | Sale | President, R&D | 47,312 0.0347% | $13.90 | $657,637 | -4.23% | ||
| 2023-03-10 | President, R&D | 1,000 0.0012% | $6.50 | $6,500 | +9.05% | |||
| 2023-03-07 | President, R&D | 2,000 0.0023% | $7.04 | $14,088 | +1.72% | |||
| 2023-03-06 | President, R&D | 3,000 0.0036% | $7.48 | $22,454 | -2.74% | |||
| 2022-03-31 | Sale | 300 0.0004% | $75.10 | $22,531 | -69.53% | |||
| 2022-01-03 | Sale | EVP, Chief Legal Officer | 5,000 0.0064% | $140.91 | $704,534 | -65.85% | ||
| 2021-12-31 | Sale | director | 3,750 0.0049% | $144.16 | $540,601 | -64.98% | ||
| 2021-12-20 | Sale | EVP, Chief Legal Officer | 5,000 0.0075% | $230.00 | $1.15M | -74.34% | ||
| 2021-12-15 | Sale | President, R&D | 1,686 0.0022% | $174.13 | $293,584 | -71.05% | ||
| 2021-12-07 | Sale | President, R&D | 8,250 0.0101% | $170.14 | $1.4M | -70.62% | ||
| 2021-12-01 | Sale | EVP, Chief Legal Officer | 5,000 0.0067% | $196.19 | $980,944 | -71.88% | ||
| 2021-11-30 | Sale | President, R&D | 8,942 0.0115% | $203.20 | $1.82M | -73.89% | ||
| 2021-11-29 | Sale | EVP, Chief Legal Officer | 5,000 0.0078% | $228.72 | $1.14M | -71.88% | ||
| 2021-11-26 | Sale | President, R&D | 2,083 0.0028% | $218.07 | $454,247 | -74.84% | ||
| 2021-11-23 | Sale | President, R&D | 8,250 0.0108% | $199.50 | $1.65M | -72.49% | ||
| 2021-11-16 | Sale | President, R&D | 8,250 0.0108% | $169.48 | $1.4M | -66.87% | ||
| 2021-11-15 | Sale | President, R&D | 1,183 0.0016% | $172.02 | $203,496 | -67.05% |
Insider Historical Profitability
| YOUNG JAMES F | director | 61760 0.0386% | $8.13 | 5 | 9 | +66.45% |
| Monath Thomas P | director | 3225366 2.0135% | $8.13 | 1 | 0 | <0.0001% |
| TANANBAUM JAMES B | director | 3151818 1.9676% | $8.13 | 1 | 0 | <0.0001% |
| DOUGLAS RICHARD | director | 550000 0.3434% | $8.13 | 7 | 0 | +19.72% |
| BOUDREAUX GAIL | director | 200000 0.1249% | $8.13 | 1 | 0 | <0.0001% |
Institutional Investor Ownership
| State Street | $80.81M | 12.04 | 16.91M | +0.78% | +$624,722.10 | <0.01 | |
| The Vanguard Group | $64.5M | 9.61 | 13.49M | -7.33% | -$5.1M | <0.01 | |
| BlackRock | $45.07M | 6.72 | 9.43M | +11.76% | +$4.74M | <0.01 | |
| Shah Capital Management | $38.8M | 5.78 | 8.12M | +4.33% | +$1.61M | 11.05 | |
| Geode Capital Management | $12.37M | 1.84 | 2.59M | +12.63% | +$1.39M | <0.01 |